Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:1008 (17 November), doi:10.1136/bmj.39394.676227.BE
| The first 150 words of the full text of this article appear below. |
The two tier testing system endorsed by the Centers for Disease Control and Prevention (CDC) has a high specificity (99%) and yields few false positives. But the tests have a uniformly miserable sensitivity (56%)—they miss 88 of every 200 patients with Lyme disease (table
). By comparison, AIDS tests have a sensitivity of 99.5%—they miss only one of every 200 AIDS cases. In simple terms, the chance of a patient with Lyme disease being diagnosed using the commercial tests approved by the Food and Drug Administration and sanctioned by the CDC is about getting heads or tails when tossing a coin, and the poor test performance assures that many patients with Lyme disease will go undiagnosed.
|
Raphael B Stricker, past president1, Lorraine Johnson, executive director2
1 International Lyme and Associated Diseases Society, San Francisco, CA 94108, USA, 2 California Lyme Disease Association, Los Angeles, CA 90068, USA
rstricker@usmamed.com
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+